Dana-Farber Cancer Institute shared a post on LinkedIn:
“New Phase 3 results from the BRUIN CLL-322 trial show that for patients whose CLL has returned or stopped responding to treatment, a time-limited 3-drug approach kept the cancer under control longer than standard therapy, without adding much toxicity.
‘This evidence aligns with what we have been observing in the clinic, which is that the current standard of care is not as effective in the modern patient population as it was in a more historical patient population,’
says Matthew S. Davids, Chief of the Division of Lymphoma.
‘This new approach is an opportunity to add another drug to standard therapy to safely extend the duration of remission, and the time-limited nature of the regimen opens up the possibility of retreatment strategies in the future.’
Other articles about Dana-Farber and Matthew Davids on OncoDaily.